Pulmatrix EBIT TCAC 10A

Que fait Pulmatrix ? Pulmatrix, Inc. generates revenue through the development and commercialization of inhaled therapeutic products for respiratory diseases. The company focuses on its proprietary iSPERSE dry powder delivery technology, which enables the delivery of small or large molecule drugs to the lungs via inhalation. Pulmatrix's therapeutic candidates include Pulmazole, PUR1800, PUR5700, PUR3000, and PUR4000, designed to address serious respiratory conditions. The company targets healthcare providers and pharmaceutical partners seeking innovative inhaled therapies for respiratory diseases. Pulmatrix's business model relies on the development of its iSPERSE technology, which is compatible with various dry powder inhaler devices and can be formulated with small molecules and biologics. The company's product pipeline consists of multiple therapeutic candidates, each representing a potential revenue stream once approved. Pulmatrix aims to partner with pharmaceutical companies to advance its drug candidates through clinical trials and eventual market entry. The company's revenue streams are derived from the potential sale of its inhaled therapeutic products, which are developed using its iSPERSE platform. Pulmatrix's focus on respiratory diseases positions it to serve patients requiring novel treatments for conditions such as asthma, COPD, and other lung-related disorders. The company's clinical stage status indicates that its products are still in development, with commercialization expected upon regulatory approval. Pulmatrix est l'une des entreprises les plus populaires sur Eulerpool.